Q-omics provides the consensus-scored MRPL43 profile across patient tissues and cancer cell-line models. MRPL43 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MRPL43 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, MRPL43 protein abundance shows 23,088 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LIHC, and LSCC as cancer lineages where MRPL43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL43 survival associations across molecular data types. MRPL43 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL43 RNA expression–survival associations across cancer types. High MRPL43 expression shows unfavorable associations in ACC, KICH and READ, but favorable associations in UCS, LGG and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MRPL43 RNA expression.
This table summarizes MRPL43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL43 shows lower tumor expression in KICH and higher tumor expression in LIHC, KIRC, HNSC, CHOL and COAD. The LIHC box plot shows higher MRPL43 RNA expression in tumor versus normal tissue (log2 FC = +1.047, t-test p < 0.001).
This table shows molecular features associated with MRPL43 in patient tissues and cancer cell lines. In patient samples, MRPL43 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL43 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
